Clene Inc. (CLNN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: Clene Inc.
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Business Overview: Clene is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics for central nervous system disorders, including ALS, Multiple Sclerosis (MS), and Parkinson's disease. The company also generates limited revenue from dietary supplements via a subsidiary and a related-party license agreement with 4Life Research LLC.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $27 | $91 | $108 | $164 |
| Net Loss | $(7,419) | $(6,785) | $(8,170) | $(17,865) |
| Loss Per Share (Basic/Diluted) | $(0.78) | $(1.06) | $(0.89) | $(2.78) |
| Operating Cash Flow | N/A | N/A | $(9,755) | $(13,438) |
| Cash & Equivalents (End of Period) | $7,285 | N/A | N/A | N/A |
| Total Debt (Notes & Convertible) | $16,127 | N/A | N/A | N/A |
Note: Debt figures represent future principal payments net of discounts. Cash balance as of June 30, 2025, was $7.3 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 70% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 34% year-to-date, driven by a 98% drop in product revenue and a 4% drop in royalty revenue from related party 4Life.
- Expense Reduction: Total operating expenses decreased 21% QoQ and 40% YTD. Research and Development (R&D) expenses fell 50% YTD, primarily due to cost-saving initiatives, reduced personnel costs, and lower manufacturing expenses, partially offset by increased ALS clinical program costs.
- Net Loss Improvement: Net loss decreased 54% YTD compared to the prior year, largely due to reduced operating expenses and a gain of $1.8 million from changes in the fair value of warrant and derivative liabilities (compared to a loss in the prior year).
- Debt Restructuring: The company repaid the 2021 Avenue Loan in December 2024 using proceeds from new Senior Secured Convertible Promissory Notes (2024 SSCP Notes).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. Cash on hand ($7.3M) is insufficient to sustain operations without additional financing. The company is required to maintain at least $2.0M in unrestricted cash to avoid accelerating debt obligations.
- Financing Activities: The company raised $5.1M via its At-The-Market (ATM) facility during the first six months of 2025. Subsequent to the quarter end, it raised an additional $1.9M via ATM and $1.5M via new senior secured convertible notes.
- Clinical Progress:
- ALS: Received FDA guidance on a potential accelerated approval pathway for CNM-Au8. Plans to submit an NDA by end of 2025 pending NfL biomarker data analysis.
- MS: Enrollment concluded for the second cohort of the REPAIR-MS Phase 2 trial; topline results expected in Q3 2025.
- Unusual Items: Significant volatility in "Other Income (Expense)" due to fair value adjustments of warrant liabilities and derivative liabilities embedded in debt instruments. Q2 2025 included a $0.5M loss on warrant liabilities and a $0.4M loss on derivative liabilities.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $7.3M cash balance against the $9.8M operating cash burn rate for the first half of 2025 and the $2.0M debt covenant minimum.
- Debt Covenants: Confirm compliance with the 2024 SSCP Notes covenants, specifically the unrestricted cash requirement and the potential for acceleration upon default.
- FDA Milestones: Monitor the outcome of the Q3 2025 FDA Type C meeting regarding the ALS NDA submission and the Q3 2025 topline results for the MS Phase 2 trial.
- Dilution Risk: Assess the impact of outstanding warrants (approx. 7.2M shares) and convertible notes (approx. 1.2M shares) on future share count, especially given the low conversion prices on recent debt instruments.
- Related Party Dependence: Evaluate the sustainability of revenue given that nearly all revenue comes from a single related party (4Life) and is subject to minimum sales commitments.